LENZ Therapeutics, Inc./$LENZ
1D1W1MYTD1Y5YMAX
Capital at risk
About LENZ Therapeutics, Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
- Ticker
- $LENZ
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 152
- Headquarters
- Solana Beach, United States
- Website
- www.lenz-tx.com
LENZ Metrics
BasicAdvanced
$130M
-
-$4.12
1.63
-
Price and volume
Market cap
$130M
Beta
1.63
52-week high
$50.40
52-week low
$4.00
Average daily volume
741K
Financial strength
Current ratio
13.553
Quick ratio
12.906
Long term debt to equity
0.001
Total debt to equity
0.003
Profitability
EBITDA (TTM)
-135.204
Gross margin (TTM)
91.74%
Net profit margin (TTM)
-586.74%
Operating margin (TTM)
-631.70%
Effective tax rate (TTM)
-0.00%
Revenue per employee (TTM)
$140,000
Management effectiveness
Return on assets (TTM)
-37.36%
Return on equity (TTM)
-59.21%
Valuation
Price to revenue (TTM)
5.884
Price to book
0.59
Price to tangible book (TTM)
0.59
Price to free cash flow (TTM)
-1.104
Free cash flow yield (TTM)
-90.56%
Free cash flow per share (TTM)
-3.74
Growth
Revenue change (TTM)
329.50%
Earnings per share change (TTM)
116.96%
Upcoming events
No upcoming events
LENZ News
AllArticlesVideos
Funds containing LENZ
AllUSDGBPEUR
Fund name | Fund size | $LENZ weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.01% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.